What is low-dose naltrexone (LDN) — and who is it actually for?

LDN has one of the most devoted followings in functional medicine — patients find it in forums, podcasts, and support groups long before they hear about it from a doctor. In two decades of practicing medicine, I’ve learned that when a medication builds that kind of grassroots reputation, it deserves a serious, honest look: what it is, why it might work, and what the evidence really says. Here’s all three.

What LDN actually is

Naltrexone is an FDA-approved medication for alcohol and opioid dependence. “Low-dose” naltrexone uses a small fraction of that standard dose — prescribed off-label, compounded specifically by a pharmacy, and individualized to the patient. At that low level, the drug stops behaving like an addiction medication and starts behaving like something else entirely: an immune and inflammation modulator.

How it’s thought to work

Two mechanisms, and both are genuinely elegant. First, a low dose blocks the body’s opioid receptors only briefly — a few hours instead of a full day — and the body responds to that short blockade by upregulating its own endorphins, your built-in pain-relief and mood chemistry. Second, and independent of that, naltrexone quiets a receptor called TLR-4 on immune cells in the brain and body, dialing down pro-inflammatory signals like TNF and IL-6. In plain language: it nudges your own systems to calm inflammation and raise your natural endorphins, rather than forcing anything from outside.

The conditions it’s used for

LDN is being used and studied across a wide range of chronic pain, autoimmune, and inflammatory conditions, including:

Some of the early findings are striking — an early Crohn’s trial reported improvement in a large majority of patients versus placebo, and arthritis registry data suggest persistent LDN users went on to need fewer painkillers and anti-inflammatories. Those signals are real, and they’re part of why interest keeps growing.

Now the honest part

A 2026 review of more than a hundred LDN studies found only a small minority were randomized controlled trials — and early positive results from uncontrolled studies were rarely replicated when placebo controls were added. The current evidence does not support LDN as routine, first-line care for any of the conditions above. Where it earns a legitimate place is as a pragmatic option in treatment-resistant cases — when standard therapies have been tried and fallen short — with its experimental status explained openly, exactly as I’m doing here. The good news on the safety side: at low doses LDN is inexpensive and generally well tolerated, with vivid dreams and headaches the most commonly reported effects and no organ toxicity or dependence reported. Modest risk, honest uncertainty, real potential in the right patient — that’s the accurate picture.

Measure, don’t guess

If you’re living with chronic pain, autoimmune disease, or inflammation that standard care hasn’t solved, LDN is a conversation worth having — but it’s the third step, not the first. The first is labs and a real evaluation, because “inflammation” has causes, and treating the root beats quieting the signal. That’s how we practice integrative medicine: conventional and complementary tools on the same table, chosen by evidence and your case — never by trend. Whether LDN belongs in your plan is a decision we make together, individualized and provided through our office, alongside the daily fundamentals that every anti-inflammatory plan stands on.

Text us at 480-485-2197 to schedule, or call. Quick response, real scheduling, no phone tree.

To Health and Wellness,
Dr. Tallman

References

  • Advances in Therapy, 2026 — low-dose naltrexone, what is the evidence, narrative review
  • Pharmacotherapy, 2018 — safety and efficacy of low-dose naltrexone in chronic pain and inflammation
  • Clinical Rheumatology, 2014 — low-dose naltrexone as a novel anti-inflammatory treatment for chronic pain
  • Current Pain and Headache Reports, 2020 — low-dose naltrexone for chronic pain, update and review
  • JAMA Dermatology, 2019 — naltrexone for chronic inflammatory dermatologic conditions
  • Journal of the American Academy of Dermatology, 2025 — low-dose naltrexone for dermatologic conditions, clinical review
Scroll to Top